Focused ultrasound devices and methods for treating hypertension
By using focused ultrasound to ablate perirenal adipose tissue, the problem of poor medication adherence and invasive treatment in existing hypertension treatments has been solved, providing a non-invasive, safe, and effective treatment method for hypertension.
Patent Information
- Application Number
- CN202680003108.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-30
- Publication Date
- 2026-11-17
AI Technical Summary
Current treatments for hypertension mainly rely on drug therapy, which suffers from poor adherence, high costs, and numerous side effects. Furthermore, existing non-invasive physical therapies, such as renal denervation, are difficult to target precisely and are also very expensive, making them difficult to adopt widely.
Focused ultrasound is used to ablate the perirenal adipose tissue surrounding the patient's kidneys. By applying energy within the acoustic focal zone using focused ultrasound waves, the perirenal adipose tissue is ablated, avoiding the kidneys and other vital tissues, thus achieving non-invasive treatment for hypertension.
It effectively treats hypertension, avoids the side effects of drug therapy, provides a non-invasive and safe treatment method, reduces treatment costs, and minimizes the occurrence of adverse reactions.
Smart Images

Figure CN123125022A_ABST
Abstract
Description
Technical Field
[0001] This application generally relates to the field of hypertension treatment, and specifically to focused ultrasound devices and methods for treating hypertension. Background Technology
[0002] Hypertension is a serious chronic disease that severely endangers human health and lifespan. Its incidence continues to rise with economic development and increased average life expectancy. The progression of hypertension is typically gradual, developing from an asymptomatic state to eventual organ damage. During the initial asymptomatic phase, patients often have low awareness of the disease. Even after diagnosis, the rate of achieving target blood pressure control remains unsatisfactory. Therefore, due to high incidence, low awareness, and poor control rates, the number of patients suffering from hypertension complications, such as stroke (vascular thrombosis or in situ thrombosis), heart failure (systolic and diastolic), and progressive renal failure, is increasing.
[0003] Currently, drug therapy is the main method for treating hypertension, but it has several problems: (1) antihypertensive drugs need to be used for life, which is inconvenient for patients and leads to poor compliance; (2) long-term antihypertensive drugs are expensive; (3) drugs have a variety of side effects. Some patients find the side effects difficult to tolerate and therefore stop the therapy. Therefore, there is an urgent need for a non-drug and physical therapy method that can replace drug therapy or serve as an effective supplement to drug therapy.
[0004] Currently, the leading technology for treating hypertension with physical energy is renal denervation (RDN). Its principle involves delivering energy (such as radiofrequency, ultrasound, chemical, or cryoablation) to the nerve plexus surrounding the renal artery wall to disrupt the sympathetic nerve fibers around the artery. Because the renal sympathetic nerves are located within the adventitia of the renal artery, approximately a few millimeters from the lumen, this target is difficult to precisely locate and treat with non-invasive external energy delivery. Therefore, all currently available solutions are invasive treatments, which can lead to adverse reactions such as renal artery stenosis. Furthermore, as an invasive procedure, RDN involves high treatment costs, typically ranging from tens of thousands to over one hundred thousand yuan, hindering its widespread adoption.
[0005] Therefore, there is a need for an effective and non-invasive physical therapy method and device for treating hypertension. Summary of the Invention
[0006] The purpose of this application is to provide an effective and non-invasive physical therapy method and a focused ultrasound device for treating hypertension.
[0007] According to one aspect of this application, a method for treating hypertension by ablating perirenal adipose tissue around a patient's kidney using a focused ultrasound device is provided. The method includes: i) positioning an acoustic focal zone generated by the focused ultrasound device within the perirenal adipose tissue surrounding the kidney, wherein the location of the acoustic focal zone is at least at a predetermined minimum distance from the renal capsule and renal fascia of the kidney; and ii) applying focused ultrasound waves to the perirenal adipose tissue within the acoustic focal zone.
[0008] According to another aspect of this application, a focused ultrasound device is provided, configured to treat hypertension by ablating perirenal adipose tissue around a patient's kidney using a focused ultrasound therapy probe. The device includes a processor configured to control the focused ultrasound device to perform the following operations: generating a target region by the focused ultrasound device for perirenal adipose tissue ablation; generating a plurality of ablation targets spatially arranged within the target region, each ablation target corresponding to a position of the acoustic focal zone of the focused ultrasound therapy probe for ablation; and applying focused ultrasound waves to each of the plurality of ablation targets to ablate the perirenal adipose tissue within the target region.
[0009] According to another aspect of this application, a focused ultrasound device is provided, configured to treat hypertension by ablating perirenal adipose tissue surrounding a patient's kidney. The focused ultrasound device includes: a treatment frame; a focused ultrasound treatment probe fixed to the treatment frame and configured to emit focused ultrasound waves to ablate perirenal adipose tissue, wherein the focused ultrasound treatment probe is movable in an axial direction perpendicular to the contact interface between the focused ultrasound device and the patient; and a first ultrasound imaging probe mounted on the treatment frame, wherein the first ultrasound imaging probe is movable in the axial direction, and the first ultrasound imaging probe and the focused ultrasound treatment probe are configured to be independently actuated to allow individual axial translation of each probe.
[0010] It should be understood that the foregoing general description and the following detailed description are merely exemplary and explanatory and do not constitute a limitation on the invention. Furthermore, the accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and, together with this specification, serve to explain the principles of the invention. Attached Figure Description
[0011] The accompanying drawings, which are incorporated herein by reference, form part of this specification. The features shown in the drawings illustrate only some embodiments of this application, and not all embodiments of this application, unless the detailed description clearly indicates otherwise, and the reader of this specification should not imply the contrary.
[0012] Figure 1and 2 A schematic diagram illustrating a hypertension treatment scenario using a focused ultrasound device to ablate the perirenal adipose tissue of a patient's kidney, according to a first embodiment of this application.
[0013] Figure 3 A schematic diagram of the tissues inside the kidney is shown.
[0014] Figure 4 An ultrasound image of the perirenal fat region at the lower pole of the kidney, generated during treatment, is shown.
[0015] Figures 5 to 7 A schematic diagram of a focused ultrasound device according to a second embodiment of this application is shown, the focused ultrasound device being configured to treat hypertension by ablating the perirenal adipose tissue surrounding the patient's kidney.
[0016] Figure 8 The changes in 24-hour mean systolic blood pressure in the treatment group and the control group were shown in a clinical study using the method for treating hypertension provided in this application.
[0017] Figure 9 The changes in 24-hour mean diastolic blood pressure in the treatment and control groups were shown in a clinical study using the method for treating hypertension provided in this application.
[0018] Throughout the accompanying drawings, the same reference numerals will be used to refer to the same or similar parts. Detailed Implementation
[0019] The following detailed description of exemplary embodiments of this application takes into account the accompanying drawings, which form a part of the description. The drawings illustrate specific exemplary embodiments in which this application may be practiced. The detailed description, including the drawings, describes these embodiments in sufficient detail to enable those skilled in the art to practice this application. Those skilled in the art may further utilize other embodiments of this application and make logical, mechanical, and other changes without departing from the spirit or scope of this application. Therefore, the reader of the following detailed description should not interpret the description in a limiting sense, and the scope of the embodiments of this application is defined only by the appended claims.
[0020] In this application, unless otherwise expressly stated, the use of the singular includes the plural form. In this application, unless otherwise stated, the use of “or” means “and / or”. Furthermore, the use of the term “comprising” is not restrictive. Additionally, unless otherwise expressly stated, terms such as “element” or “assembly” cover both elements and assemblies comprising one unit and elements and assemblies comprising more than one sub-unit. Furthermore, the section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described.
[0021] As used herein, for ease of description, spatial relative terms such as “below,” “under,” “above,” “upper,” “upper,” “lower,” “left,” “right,” “vertical,” “horizontal,” and “side” may be used to describe the relationship between an element or feature and another element (or feature) or feature (or feature), as shown in the diagrams. In addition to the orientations depicted in the diagrams, the spatial relative terms are intended to cover different orientations of the device in use or operation. The device may be oriented in other ways (rotated 90 degrees or in other orientations), and the spatial relative descriptors used herein shall be interpreted accordingly. It should be understood that when an element is referred to as “connected to” or “coupled to” another element, the element may be directly connected to or coupled to the other element, or there may be intermediate elements present.
[0022] As stated above, there is a clear and urgent need for effective and non-invasive physical therapy methods and devices for treating hypertension. This application provides a novel non-invasive treatment method and focused ultrasound device for treating hypertension. Specifically, the treatment method treats hypertension by ablating the perirenal adipose tissue of a patient's kidney using a focused ultrasound device. During treatment, the acoustic focal zone generated by the focused ultrasound device is positioned within the perirenal adipose tissue of the kidney. The focused ultrasound device then applies focused ultrasound waves within the acoustic focal zone to the perirenal adipose tissue, thereby ablating the perirenal adipose tissue. Based on clinical trial results, the focused ultrasound device and treatment method for treating hypertension provided in this application can effectively achieve the goal of treating hypertension, with no serious adverse reactions observed, thus demonstrating significant clinical benefit.
[0023] Figure 1 and 2 A schematic diagram illustrating a hypertension treatment scenario using a focused ultrasound device to ablate the perirenal adipose tissue of a patient's kidney according to a first embodiment of this application. Figure 3 A schematic diagram of the internal tissues of the kidney is shown, and Figure 4 An ultrasound image of the perirenal fat region at the lower pole of the kidney, generated during treatment, is shown.
[0024] like Figure 1 and 2As shown, a focused ultrasound device with a focused ultrasound therapy probe 101 is provided to ablate perirenal adipose tissue surrounding a patient's kidney. In some embodiments, the perirenal adipose tissue is adipose tissue located at the lower pole of the kidney. During treatment, the focused ultrasound device is configured to deliver ultrasound energy through a posterior or lateral approach to establish an acoustic focusing path. For example, the focused ultrasound therapy probe 101 is typically positioned on the skin surface of the patient's side or back, near the left kidney 92 or right kidney 91. In this way, focused ultrasound waves generated by the focused ultrasound therapy probe 101 can be transmitted from the side or back of the patient's body into the interior of the body. During treatment, the focused ultrasound therapy probe 101 of the focused ultrasound device generates an acoustic focal zone 10101. By moving the focused ultrasound therapy probe 101, the acoustic focal zone 10101 can be positioned within the perirenal adipose tissue surrounding the kidney. Focused ultrasound waves are then applied to the perirenal adipose tissue within the acoustic focal zone 10101, thereby ablating the perirenal adipose tissue.
[0025] Specifically, Figure 3 The diagram shows the renal tissues. The tissues surrounding the left kidney 92 include the left adrenal gland 921, the left perirenal fat 922, and the left perirenal lower pole fat 923. The tissues surrounding the right kidney 91 include the right adrenal gland 911, the right perirenal fat 912, and the right perirenal lower pole fat 913.
[0026] In this embodiment, perirenal adipose tissue refers to the adipose tissue located between the renal fibrous capsule (a thin membrane tightly adhered to the renal parenchyma) and the renal fascia (Gerota's fascia). Perirenal adipose tissue includes both pararenal fat and lower pole perirenal fat. However, since pararenal fat is usually thinner and adjacent to the kidney, in this treatment method, treatment applied to perirenal adipose tissue can specifically refer to treatment applied only to the lower pole perirenal fat to avoid potential damage to the kidney. Furthermore, lower pole perirenal fat refers to the perirenal fat located vertically below the lower pole of the kidney and close to the pelvic cavity.
[0027] in addition, Figure 4 The image shows an ultrasound image of the perirenal fat region at the lower pole of the kidney during treatment. (Example) Figure 4 As shown, the ultrasound images reveal the outlines of the kidney boundary 901, the perirenal fat boundary 902 at the lower pole of the kidney, and the psoas muscle boundary 903. Typically, the perirenal fat 913 at the lower pole of the right kidney 91 is adjacent to the hepatic flexure of the colon, and the perirenal fat 923 at the lower pole of the left kidney 92 is adjacent to the jejunum and the left flexure of the colon. Therefore, the acoustic focusing path of the focused ultrasound should avoid the hepatic flexure of the colon and the jejunum to ensure treatment safety and minimize the ultrasound dose delivered to areas outside the perirenal fat at the lower pole of the kidney.
[0028] Furthermore, considering the positioning accuracy achievable with current focused ultrasound technology, and focal zone deviations caused by tissue heterogeneity and individual anatomical differences along the ultrasound transmission path, boundaries should be established to define the actual treatment area of the perirenal fat at the lower pole of the kidney, which should be separated from vital renal tissues. This helps ensure treatment safety and minimizes ultrasound dose delivered to areas outside the perirenal fat at the lower pole of the kidney. For example, the location of the acoustic focal zone 10101 should be at least a predetermined minimum distance from the renal capsule and renal fascia.
[0029] Typically, the thermal effect of the acoustic focal zone 10101 extends further along its axial direction than in a direction perpendicular to that axis. Therefore, the distance between the acoustic focal zone 10101 and vital renal tissues along its axial direction should be greater than the distance in a direction perpendicular to its axial direction. Preferably, the acoustic focal zone 10101 may be spaced at least 3 mm from the renal capsule and renal fascia along its axial direction. Furthermore, the acoustic focal zone 10101 may be spaced at least 2 mm from the renal capsule and renal fascia in a direction perpendicular to its axial direction. Additionally, in some embodiments, during treatment, the acoustic focusing path used to form the acoustic focal zone 10101 is selected to be away from the hepatic flexure of the colon and the jejunum to avoid any potential damage to the hepatic flexure or jejunum. Furthermore, the acoustic focal zone 10101 should be positioned at least a predetermined minimum distance from the psoas major muscle. Preferably, in the direction along the axis of the acoustic focal zone 10101, the acoustic focal zone 10101 should be spaced at least 1.5 mm from the psoas major muscle. In the direction perpendicular to the axis of the acoustic focal zone 10101, the acoustic focal zone 10101 should be spaced at least 1 mm from the psoas major muscle.
[0030] like Figure 1 and 2 As shown, in this embodiment, the acoustic focal zone 10101 of the focused ultrasound therapy probe 101 is located within the perirenal adipose tissue of the left kidney 92 or the right kidney 91 during treatment. To ensure the efficacy and safety of the treatment process, the irradiation path of the focused ultrasound waves generated by the focused ultrasound therapy probe 101 should avoid areas that may cause strong ultrasound reflections, such as bones, kidneys, and gases.
[0031] During treatment, the focused ultrasound therapy probe 101 delivers focused ultrasound waves to the perirenal adipose tissue of the left kidney 92 or right kidney 91 to ablate nerve fibers therein. In this embodiment, the acoustic focal domain 10101 is first positioned within a target volume of the perirenal adipose tissue surrounding the kidney, and then focused ultrasound waves are applied to ablate the perirenal adipose tissue within the acoustic focal domain 10101, thereby ablating the target volume of the perirenal adipose tissue. The acoustic focal domain 10101 is then moved to the next target volume to repeat the ablation process, so as to further ablate additional target volumes of perirenal adipose tissue using the acoustic focal domain 10101. As the treatment progresses, more target volumes of perirenal adipose tissue are ablated sequentially, with the acoustic focal domain 10101 being repositioned each time, until at least a portion of the perirenal adipose tissue surrounding the kidney has been traversed by the acoustic focal domain 10101. In some preferred embodiments, the acoustic focal zone 10101 of the focused ultrasound therapy probe 101 is moved to cover the entire perirenal adipose tissue of the left kidney 92 and / or the right kidney 91, thereby ablating as many nerve fibers as possible within the perirenal adipose tissue, for example, more than one-third of the nerve fibers within the perirenal adipose tissue, to improve therapeutic efficacy.
[0032] Furthermore, during treatment, when focused ultrasound is applied to the perirenal adipose tissue within the acoustic focal zone 10101, the temperature of the perirenal adipose tissue irradiated by the focused ultrasound rises to 40°C to 70°C, or more preferably, 45°C to 55°C. The irradiation duration of the perirenal adipose tissue within each acoustic focal zone 10101 is between 1 second and 120 seconds. Additionally, the focused ultrasound is applied to the perirenal adipose tissue such that the focused ultrasound power reaching the perirenal adipose tissue is in the range between 5 W and 100 W. Furthermore, the focused ultrasound is applied to the perirenal adipose tissue within the acoustic focal zone 10101 such that the maximum sound intensity of each acoustic focal zone 10101 reaching the perirenal adipose tissue is between 100 W / cm². 2 With 4000 W / cm 2 The frequency range is between 0.8 MHz and 1.7 MHz. Focused ultrasound can be applied at frequencies between 0.8 MHz and 1.7 MHz, and the ultrasound pulses of focused ultrasound can be continuous or discontinuous.
[0033] Figures 5 to 7 A schematic diagram of a focused ultrasound device according to a second embodiment of this application is shown, the focused ultrasound device being configured to treat hypertension by ablating the perirenal adipose tissue surrounding the kidneys of a patient. More specifically, Figure 5 The overall structure of the integrated treatment head of the focused ultrasound device was demonstrated. Figure 6 Showing Figure 5 The cross-sectional view of the integrated treatment head shown is as follows. Figure 7 A cross-sectional view of a focused ultrasound device, including an integrated treatment head and functional modules, is shown.
[0034] like Figure 5 As shown, an integrated treatment head 100 including key treatment components is provided. The integrated treatment head 100 includes a treatment frame 1001 for mechanically supporting and moving the key treatment components to a predetermined position during treatment. Specifically, a focused ultrasound therapy probe 101 is fixed to the treatment frame 1001 and configured to emit focused ultrasound waves to ablate perirenal adipose tissue, and the focused ultrasound therapy probe 101 is movable in an axial direction X parallel to the axis of the focused ultrasound therapy probe 101. More specifically, the axis of the focused ultrasound therapy probe 101 refers to the central axis of the focused ultrasound therapy probe 101. Figure 5 As shown, the focused ultrasound therapy probe 101 generates an acoustic focal zone 10101 during treatment. Furthermore, a first ultrasound imaging probe 102 is mounted on the treatment frame 1001 and is movable in the axial direction X. The first ultrasound imaging probe 102 is configured to acquire ultrasound images when generating ablation targets for ablation of perirenal adipose tissue. In other words, the first ultrasound imaging probe 102 is movable in the same axial direction X as the focused ultrasound therapy probe 101. During treatment, the focused ultrasound therapy probe 101 and the first ultrasound imaging probe 102 can move towards and away from the operating plane in the axial direction X at different stages of the treatment process. Furthermore, the first ultrasound imaging probe 102 and the focused ultrasound therapy probe 101 can be driven independently to allow individual axial movement of each probe, and they can also move relative to each other.
[0035] Furthermore, in this embodiment, the integrated treatment head 100 may include a first motor 110, which is mounted on the treatment frame 1001 and configured to control the first ultrasound imaging probe 102 to reciprocate along the axial direction X. Additionally, the integrated treatment head 100 further includes a second motor 111, which is mounted on the treatment frame 1001 and configured to control the focused ultrasound treatment probe 101 to reciprocate along the axial direction X.
[0036] Furthermore, the integrated treatment head 100 may include a water tank 104 containing acoustic coupling water, and a water bladder 105 mounted together with and below the water tank 104. The water bladder 105 is configured to contact the patient's skin during treatment. Both the water tank 104 and the water bladder 105 are mounted on the treatment frame 1001, allowing them to be moved to predetermined positions for effective treatment of the patient. During treatment, the water bladder 105 is filled with acoustic coupling water. In this embodiment, the first ultrasound imaging probe 102 and the focused ultrasound treatment probe 101 may be mounted within the water tank 104, or more specifically, placed in the acoustic coupling water. It should be noted that both the first ultrasound imaging probe 102 and the focused ultrasound treatment probe 101 are designed to be waterproof. In this way, during treatment, ultrasound waves emitted by the focused ultrasound treatment probe 101 and the first ultrasound imaging probe 102 can be transmitted to the patient through the acoustic coupling water within the water tank 104 and the water bladder 105.
[0037] In addition, such as Figure 5 As shown, the first camera 112 and the second camera 113 can be mounted on two opposite sides of the first ultrasound imaging probe 102. During treatment, the water balloon 105 is in direct contact with the patient's skin. The first camera 112 and the second camera 113 can be positioned facing the contact surface between the water balloon 105 and the patient's skin to obtain an image of the contact surface. In this way, the coupling state between the water balloon 105 and the patient's skin surface can be assessed based on the number and size of bubbles measured in the image. In some cases where there are too many bubbles or excessively large bubbles, the transmission of ultrasound waves into the patient's body may be adversely affected.
[0038] Furthermore, in some embodiments, a pressure sensor 106 may be installed within the water tank 104. The pressure sensor 106 is configured to measure the pressure within the water tank 104 caused by the acoustically coupled water and the water bladder 105. Additionally, a temperature sensor 107 may be installed within the water tank 104. The temperature sensor 107 is configured to monitor the temperature of the acoustically coupled water.
[0039] Furthermore, in some embodiments, the integrated treatment head 100 also includes a second ultrasound imaging probe 103, which is mounted outside the treatment frame 1001. For example, optionally, the second ultrasound imaging probe 103 can be mounted on a probe fixing device 108 extending out of the treatment frame 1001. Therefore, the second ultrasound imaging probe 103 can be moved and supported by the probe fixing device 108 to capture images from an angle different from or supplementing the angle of the first ultrasound imaging probe 102. Furthermore, the axis of the second ultrasound imaging probe 103, which can be controlled by the probe fixing device 108, always passes through the acoustic focal zone 10101 of the focused ultrasound treatment probe 101. In this way, the second ultrasound imaging probe 103 can be used to acquire ultrasound images when significant artifacts are present in the ultrasound images obtained through the first ultrasound imaging probe 102.
[0040] like Figure 7 As shown, the focused ultrasound device also includes functional modules for controlling and adjusting the aforementioned key treatment components. Specifically, the focused ultrasound device includes a control module 200, which includes at least one processor. Multiple control programs and control commands can be integrated within the at least one processor to operatively control other functional modules.
[0041] More specifically, the focused ultrasound device includes a therapeutic ultrasound drive module 300 connected to a focused ultrasound therapeutic probe 101. The therapeutic ultrasound drive module 300 receives control commands from a control module, sends electrical pulse signals to the focused ultrasound therapeutic probe 101, and drives the focused ultrasound therapeutic probe 101 to emit therapeutic ultrasound waves towards the patient to ablate the perirenal adipose tissue surrounding the patient's kidney. Furthermore, during treatment, the focused ultrasound therapeutic probe applies ultrasound waves at a frequency between 0.8 MHz and 1.7 MHz, and the ultrasound pulses can be continuous or discontinuous. Additionally, the focused ultrasound waves are applied to the perirenal adipose tissue such that the focused ultrasound acoustic power reaching the perirenal adipose tissue is between 5 W and 100 W. Moreover, the focused ultrasound waves are applied to the perirenal adipose tissue within each acoustic focal zone 10101 such that the maximum acoustic intensity of the acoustic focal zone 10101 reaching the perirenal adipose tissue is between 100 W / cm². 2 With 4000 W / cm 2 Within the range between. In this embodiment, the above-mentioned parameters of the focused ultrasound can be preset in the therapeutic ultrasound drive module 300 and controlled, for example, by the control module 200.
[0042] Furthermore, the focused ultrasound device includes an imaging ultrasound drive module 400, which is connected to the first ultrasound imaging probe 102 and the second ultrasound imaging probe 103 and receives control commands from the control module. During treatment, the imaging ultrasound drive module 400 sends electrical pulse signals to the first ultrasound imaging probe 102 and the second ultrasound imaging probe 103 to drive them to emit imaging ultrasound waves. Additionally, the imaging ultrasound drive module 400 captures the return ultrasound signals received by the first ultrasound imaging probe 102 and the second ultrasound imaging probe 103. By processing the return ultrasound signals, the imaging ultrasound drive module 400 generates corresponding ultrasound images for real-time monitoring and guidance.
[0043] Additionally, the focused ultrasound device includes a mechanical module 500 connected to the treatment frame 1001. During treatment, the mechanical module 500 receives control commands from the control module and controls the movement of key components of the treatment frame 1001 and the integrated treatment head 100 via a robotic arm. Therefore, the mechanical module 500 can also be referred to as a robotic arm module. In this embodiment, key components of the integrated treatment head 100, such as the focused ultrasound treatment probe 101, the first ultrasound imaging probe 102 or the second ultrasound imaging probe 103, the water tank 104, and the water bladder 105, can perform three-dimensional linear motion and three-dimensional angular rotation based on the control of the mechanical module 500, so that each key component can reach its corresponding position during treatment.
[0044] Furthermore, the focused ultrasound device may include a water treatment module 600 connected to the water tank 104 via a first water connector 114 and a second water connector 115 located on the water tank 104. More specifically, the focused ultrasound device receives acoustic-coupled water from the water tank 104 via the first water connector 114, removes gas from the acoustic-coupled water to obtain degassed acoustic-coupled water, and then delivers the degassed acoustic-coupled water to the water tank 104 via the second water connector 115. In some alternative embodiments, the acoustic-coupled water before and after the degassed process may be transferred into or out of the water tank 104 via the same water connector. In some preferred embodiments, the dissolved oxygen content in the degassed acoustic-coupled water may be less than or equal to 4 mg / L. Additionally, in some embodiments, the water treatment module is connected to a pressure sensor 106 and a temperature sensor 107. Therefore, the water treatment module can automatically adjust the volume of acoustic-coupled water in the water tank 104 based on the pressure measured by the pressure sensor 106. This helps maintain a stable pressure within the water tank 104, thereby preventing potential tissue displacement due to excessive pressure applied to the patient. Furthermore, the water treatment module can regulate the temperature of the acoustic coupling water by heating or cooling it according to the temperature measured by the temperature sensor 107 within the water tank 104. This ensures a stable temperature of the acoustic coupling water within the water tank 104, thereby preventing a shift in the acoustic focal zone 10101 due to excessively cold or hot acoustic coupling water and avoiding thermal damage to the patient's skin. In this embodiment, the water treatment module 600 can receive control commands from the control module 200 for temperature and pressure regulation and the degassing process of the acoustic coupling water.
[0045] This application also provides a method of operating the focused ultrasound device in any of the above embodiments for ablating perirenal adipose tissue around a patient's kidney to treat hypertension. In some embodiments, control commands for operating the focused ultrasound device during treatment may be executed by the processor of the focused ultrasound device.
[0046] In some embodiments, during treatment, a second ultrasound imaging probe 103 can be used to locate an acoustic window from the patient's back, abdomen, or waist, the acoustic window being adapted to obtain clear ultrasound images of the perirenal adipose tissue to be ablated around the kidney. The kidney may be the left kidney 92 and / or the right kidney 91.
[0047] In some embodiments, the second ultrasound imaging probe 103 can be used to identify suitable acoustic window sections of the kidney and surrounding perirenal adipose tissue along different directions of the kidney. More specifically, multiple first acoustic window sections (referred to as "first acoustic window sections" for simplicity) of the kidney and surrounding perirenal adipose tissue are acquired, and each first acoustic window section is perpendicular to a direction parallel to the short axis of the kidney (referred to as a first direction). Among the multiple first acoustic window sections, the first acoustic window section having the largest cross-sectional area of the perirenal adipose tissue is selected and designated as the designated short-axis acoustic section of the kidney and surrounding perirenal adipose tissue. Similarly, multiple second acoustic window sections (referred to as "second acoustic window sections" for simplicity) of the kidney and surrounding perirenal adipose tissue are acquired, and each second acoustic window section is perpendicular to a direction parallel to the long axis of the kidney (referred to as a second direction). Among the multiple second acoustic window sections, the second acoustic window section having the largest cross-sectional area of the perirenal adipose tissue is selected and designated as the designated long-axis acoustic section of the kidney and surrounding perirenal adipose tissue. In this embodiment, the intersection of the designated short-axis acoustic section and the designated long-axis acoustic section of the kidney and surrounding perirenal adipose tissue is defined as a suitable acoustic window location.
[0048] Next, the integrated treatment head 100 is moved to a suitable acoustic window location, ensuring direct contact between the water balloon 105 and the patient's skin surface. During this process, the first camera 112 and the second camera 113 are positioned towards the contact surface between the water balloon 105 and the patient's skin to obtain an image of the contact surface, thereby generating an image of the contact interface. In this way, the coupling state between the water balloon 105 and the patient's skin surface can be assessed based on the number and size of bubbles measured in the image. In some cases where there are too many bubbles or excessively large bubbles, ultrasound transmission into the patient's body may be adversely affected. If too many bubbles are detected, the coupling state can be adjusted via a water treatment module or manual intervention before continuing operation.
[0049] Next, the integrated treatment head 100 is moved to a position such that the imaging field of the first ultrasound imaging probe 102 passes through a designated short-axis acoustic section of the kidney and perirenal adipose tissue. In this way, the first ultrasound imaging probe 102 can generate a first ultrasound image showing the kidney and perirenal adipose tissue along the designated short-axis acoustic section. The boundary of the perirenal adipose tissue, referred to as the designated short-axis boundary of the perirenal adipose tissue, can then be obtained from the first ultrasound image.
[0050] Next, the relative orientation between the integrated treatment head 100 and the kidney is adjusted such that the imaging field of the first ultrasound imaging probe 102 passes through a designated long-axis acoustic section of the kidney and perirenal adipose tissue. In this manner, the first ultrasound imaging probe 102 generates a second ultrasound image showing the kidney and perirenal adipose tissue along the designated long-axis acoustic section. The boundary of the perirenal adipose tissue, referred to as the designated long-axis boundary of the perirenal adipose tissue, can then be obtained from the second ultrasound image.
[0051] In this manner, a target region for perirenal adipose tissue ablation can be generated by a focused ultrasound device based on designated short-axis and long-axis boundaries of the perirenal adipose tissue. More specifically, the enclosed region of the designated short-axis boundary of the perirenal adipose tissue is extended along a first direction for a length equal to the length of the enclosed region of the designated long-axis boundary of the perirenal adipose tissue along the first direction to obtain a first three-dimensional region. Similarly, the enclosed region of the designated long-axis boundary of the perirenal adipose tissue is extended along a second direction for a length equal to the length of the enclosed region of the designated short-axis boundary of the perirenal adipose tissue along the second direction to obtain a second three-dimensional region. Finally, the first and second three-dimensional regions are combined to generate the target region.
[0052] In some other embodiments, the target region can also be generated directly using three-dimensional image reconstruction techniques, such as ultrasound imaging, MRI imaging, CT imaging, or X-ray imaging. In this way, the target region of perirenal fat can be depicted. Furthermore, by using these three-dimensional imaging techniques with real-time feedback, the acoustic focal zone 10101 of the focused ultrasound probe can be precisely guided and positioned within the target region.
[0053] In some embodiments, the thickness of the muscle layer and the thickness of the soft tissue layer can be measured on a first or second ultrasound image. Additionally, the vertical distance from the lower edge of a designated short-axis boundary or a designated long-axis boundary of the perirenal adipose tissue to the skin surface can be measured on the corresponding first or second ultrasound image. Next, the ultrasound energy attenuation coefficient for the corresponding ultrasound irradiation path can be calculated based on the measured thickness of the muscle layer, the thickness of the soft tissue layer, and the acoustic attenuation coefficient of the corresponding tissue. The ultrasound energy attenuation coefficient is used to compensate for a preset focused ultrasound power or the maximum acoustic intensity of the acoustic focal zone to ensure that sufficient ultrasound energy reaches the perirenal adipose tissue region.
[0054] Next, multiple ablation targets are generated and arranged in space within the target area. Here, each ablation target corresponds to the position where the acoustic focal zone 10101 of the focused ultrasound therapy probe 101 is placed for ablation each time. In some embodiments, each ablation target corresponds to the center of the acoustic focal zone 10101. Specifically, the details of the process for generating the multiple ablation targets are shown below.
[0055] In some embodiments, the control program of the control module 200 of the focused ultrasound device can implement predetermined parameters set by the user for ablation via the focused ultrasound treatment probe 101. The predetermined parameters may include focused ultrasound acoustic power, maximum acoustic intensity of the acoustic focal zone 10101, irradiation duration, or the target area range for generating ablation targets. Furthermore, the predetermined parameters may further include a predetermined minimum interval distance between adjacent ablation targets or a predetermined boundary interval distance between adjacent acoustic focal zones 10101 corresponding to adjacent ablation targets. More specifically, the predetermined boundary interval distance between adjacent acoustic focal zones 10101 may include row spacing, column spacing, and layer spacing. In some preferred embodiments, the predetermined boundary interval distance between adjacent acoustic focal zones 10101 is less than 10 mm. In some embodiments, the predetermined boundary interval distance between adjacent acoustic focal zones 10101 is in the range of 1 mm to 5 mm. Next, multiple initial ablation targets are generated based on the predetermined parameters implemented by the control program of the control module 200, each initial ablation target corresponding to one acoustic focal zone 10101.
[0056] Next, the integrated treatment head 100 is moved so that the imaging field of the first ultrasound imaging probe 102 scans each of the plurality of initial ablation targets, and an ultrasound image is generated by the first ultrasound imaging probe 102. Based on these ultrasound images, it is verified whether each of the plurality of initial ablation targets is actually located within the target area. Based on this, if it is determined that an initial ablation target is outside the target area, the initial ablation target is deleted by the control program. Finally, some initial ablation targets that fall outside the target area are deleted, thereby automatically generating multiple ablation targets for ablation of perirenal adipose tissue. In this way, the safety and efficacy of focused ultrasound irradiation performed by the focused ultrasound treatment probe 101 can be guaranteed.
[0057] In some other embodiments, the control program uses image processing techniques (including boundary recognition techniques based on deep learning, machine learning, image recognition, or similar techniques) to automatically identify the boundaries of perirenal adipose tissue (such as perirenal fat at the lower pole of the kidney) on ultrasound images. Additionally, the control program determines whether each initial ablation target falls within the target area enclosed by this boundary. The control program automatically removes portions of the initial ablation targets that fall outside the target area to generate multiple ablation targets for ablation.
[0058] Next, the second ultrasound imaging probe 103 can be moved to make direct contact with the patient's skin surface. Subsequently, focused ultrasound waves are applied to each of the plurality of ablation targets using the focused ultrasound treatment probe 101 to ablate the perirenal adipose tissue within the target area. Here, with each ablation, the acoustic focal domain 10101 is positioned at one of the plurality of ablation targets to achieve ablation of the target volume during treatment.
[0059] In some embodiments, the control program can control the acoustic focal zone 10101 of the focused ultrasound treatment probe 101 to sequentially move to positions corresponding to ablation targets adjacent to the current ablation target via the mechanical module 500 of the focused ultrasound device. In this way, focused ultrasound waves can be applied sequentially to each of the plurality of ablation targets. In some other embodiments, the movement of the acoustic focal zone 10101 can employ a non-adjacent skip pattern. In other words, focused ultrasound waves can be applied to each of the plurality of ablation targets such that non-adjacent ablation targets are irradiated sequentially. Alternatively, in one embodiment, the ablation target furthest from the current ablation target is selected as the next ablation target to be ablated using the acoustic focal zone 10101, thereby mitigating excessive heat buildup on the patient's skin and tissues due to irradiation of adjacent ablation targets. In this manner, multiple target volumes of perirenal adipose tissue are continuously ablated. During this ablation process, the acoustic focal domain 10101 is repositioned each time until at least a portion of the perirenal adipose tissue has been traversed by the acoustic focal domain 10101, thereby completing the ablation of a sufficient number of nerve fibers within that portion of the perirenal adipose tissue. In some embodiments, the execution sequence of focused ultrasound irradiation at each ablation target point via the acoustic focal domain 10101 can be set by the user and implemented through a control program during treatment.
[0060] In some embodiments, the focused ultrasound power or the maximum acoustic intensity of the acoustic focal zone 10101 and the irradiation duration can be preset according to treatment requirements. The preset focused ultrasound power or the preset maximum acoustic intensity of the acoustic focal zone 10101 and the preset irradiation duration can be compensated by the control program based on the ultrasound energy attenuation coefficient to ensure that sufficient ultrasound energy ultimately reaches the perirenal adipose tissue. Based on the compensated focused ultrasound power or the compensated maximum acoustic intensity of the acoustic focal zone 10101 and the compensated irradiation duration, the control program sends corresponding electrical pulse signals with appropriate intensity levels and timings to the focused ultrasound treatment probe 101 through the treatment ultrasound drive module 300, thereby generating focused ultrasound waves with the required energy to the perirenal adipose tissue. It can also be understood that in some alternative embodiments, the compensation for the focused ultrasound power, the maximum acoustic intensity of the acoustic focal zone 10101 and the irradiation duration can be omitted. The control program can send corresponding electrical pulse signals with appropriate intensity levels and timings to the focused ultrasound treatment probe 101 through the treatment ultrasound drive module 300 based on the focused ultrasound power or the maximum acoustic intensity of the acoustic focal zone 10101 and the irradiation duration.
[0061] In some preferred embodiments, during focused ultrasound irradiation at each ablation target, a second ultrasound imaging probe 103 can be used to acquire real-time ultrasound images of the ablation target and its surrounding area. Users, such as doctors, can use these ultrasound images to observe the precise location corresponding to each ablation target and the ablation effect in real time, thereby ensuring the safety and efficacy of the treatment process.
[0062] In some embodiments, focused ultrasound is applied such that the focused ultrasound power reaching the perirenal adipose tissue is in the range of 5W to 100W. Furthermore, the maximum acoustic intensity at the acoustic focal zone reaching the perirenal adipose tissue is between 100 W / cm². 2 With 4000 W / cm 2 The frequency of the focused ultrasound is within the range of 0.8 MHz to 1.7 MHz.
[0063] In some other embodiments, multiple ablation targets can be generated in space within the target region in an alternative manner. More specifically, multiple initial thermal focal zones 10101 of specified sizes are generated in space within the target region. Specifically, a thermal focal zone 10101 is defined as a geometric region of biological tissue that reaches a target temperature within a specified duration of ultrasound irradiation. Here, each thermal focal zone 10101 corresponds to an initial ablation target for generating the corresponding initial thermal focal zone 10101. In this embodiment, the specified size of the initial thermal focal zone 10101 is determined based on preset size parameters, which may include the temperature rise value of the corresponding initial ablation target, the target temperature of the corresponding initial ablation target, and the thermal conductivity of the perirenal adipose tissue. In some embodiments, the temperature rise value of the corresponding initial ablation target, the target temperature of the corresponding initial ablation target, and the thermal conductivity of the perirenal adipose tissue may be pre-measured by the user or preset and obtained by a control program. Furthermore, multiple initial thermal focal zones 10101 are generated in space within the target region based on a predetermined boundary spacing distance between adjacent initial thermal focal zones 10101. The predetermined boundary spacing between adjacent initial thermal focal zones 10101 may include row spacing, column spacing, and layer spacing, which can be preset by the user and obtained through a control program. Therefore, multiple initial ablation target points are formed and arranged within the target area to generate the corresponding initial thermal focal zones 10101. In some embodiments, the user may also preset the target area range and obtain it through a control program to generate the multiple initial thermal focal zones 10101.
[0064] Next, a portion of the initial ablation target points corresponding to the initial thermal focal zone 10101 falling outside the target area are deleted, thereby generating multiple ablation target points. Next, focused ultrasound is applied to each of the multiple ablation target points to ablate the perirenal adipose tissue within the target area. The specific methods for generating the multiple ablation target points and the manner in which focused ultrasound is applied to the perirenal adipose tissue can be similar to those described below, and for the sake of brevity, will not be repeated here.
[0065] In some preferred embodiments, during the traversal of the target region by the acoustic focal domain 10101, the spacing between the boundaries of adjacent thermal focal domains 10101 corresponding to adjacent ablation targets should be sufficiently small, thereby maximizing the ablation of nerve fiber portions within the perirenal adipose tissue. In the best embodiment, the boundaries of adjacent thermal focal domains 10101 corresponding to two adjacent ablation targets may intersect or be tangent to each other.
[0066] Clinical studies will be conducted to test the efficacy and safety of the focused ultrasound device provided in this application and the method of treating hypertension by ablation of perirenal fat using the focused ultrasound device.
[0067] More specifically, this is a multicenter, double-blind, randomized, sham-operated, drug-free clinical study. Subjects were treated with the focused ultrasound device and method for treating hypertension by irradiating perirenal adipose tissue (hereinafter referred to as "treatment") provided by this invention. During treatment, nerve fibers within the perirenal adipose tissue at the lower pole of both the left and right kidneys were ablated to evaluate the efficacy and safety of the focused ultrasound device and method for treating hypertension according to this application. Subjects were patients aged 18 to 65 years with uncontrolled essential hypertension. All subjects were not taking antihypertensive medication or had stopped taking such medication for at least one month, and their blood pressure remained uncontrolled.
[0068] The clinical study recruited a total of 80 eligible participants across four centers in China, who were randomly assigned in a 1:1 ratio to either the test group (hereinafter referred to as the "FPU-iPRATM group") or the sham-operated control group (hereinafter referred to as the "sham-operated group"). The primary efficacy endpoint in the clinical study was the change in 24-hour mean systolic blood pressure (24h-ASBP) at one month of follow-up. Secondary efficacy endpoints included the change in 24h-ASBP at three months of follow-up, the change in office systolic blood pressure (OSBP) at one and three months of follow-up, and the change in 24-hour mean diastolic blood pressure (24h-ADBP) at one and three months of follow-up. The safety endpoint was the incidence of serious adverse events (such as acute renal failure, acute intestinal perforation, thromboembolic events, etc.) within three months after the end of treatment.
[0069] Between September 1, 2023 and January 16, 2025, a total of 80 participants were successfully enrolled and randomly assigned to either the FPU-iPRATM group (n = 40) or the sham surgery group (n = 40). Seventy-nine participants (98.8%) received treatment and completed the clinical study, including 39 participants who received a single FPU-iPRATM treatment and 40 participants who received sham surgery. Three participants were excluded from the final analysis of the clinical study due to a measurement device malfunction. Therefore, the FPU-iPRATM group (n = 39) and the sham surgery group (n = 37) were included in the final analysis.
[0070] Regarding the primary efficacy endpoint, such as Figure 8 As shown, at one month after treatment, the difference in 24h-ASBP reduction in the FPU-iPRATM group compared with the sham surgery group was -2.82 mmHg [IQR -5.34, -0.30]; P = 0.0288, indicating a statistically significant difference.
[0071] like Figure 9As shown, for the secondary efficacy endpoint, at three months post-treatment, the inter-group difference in the reduction of 24h-ASBP from baseline was -4.42 mmHg [IQR -6.75, -1.68]; P = 0.0007, indicating a statistically significant difference. At one month post-treatment, the inter-group difference in the reduction of 24h-ADBP from baseline was -2.88 mmHg [IQR -4.80, -0.97]; P = 0.0034. At three months post-treatment, the inter-group difference reached -3.76 mmHg [IQR -5.68, -1.85]; P = 0.0001. Statistically significant differences were observed at both one and three months post-treatment, with the reduction in 24h-ADBP showing a steady downward trend.
[0072] Regarding safety endpoints, no serious adverse events were observed in either group. The most common adverse event was mild low back pain following treatment, a typical response to exposure to focused ultrasound irradiation. Furthermore, all adverse events resolved spontaneously within one month.
[0073] Based on this clinical study, it can be concluded that the focused ultrasound device and the method for treating hypertension by ablating perirenal fat using focused ultrasound provided in this application can effectively achieve the goal of treating hypertension, with no serious adverse reactions observed, thus demonstrating significant benefits. As a non-invasive treatment method, the focused ultrasound device and the method for treating hypertension by ablating perirenal fat using focused ultrasound have the advantage of low treatment cost, which is conducive to large-scale promotion.
[0074] Although exemplary methods and focused ultrasound devices for treating hypertension have been described in conjunction with the accompanying drawings, those skilled in the art will understand that modifications and adjustments can be made to the methods and focused ultrasound devices for treating hypertension without departing from the scope of the invention.
[0075] Various embodiments have been described herein with reference to the accompanying drawings. However, it will be apparent that various modifications and changes can be made thereto, and other embodiments can be implemented, without departing from the broad scope of the invention as set forth in the appended claims. Furthermore, other embodiments will be apparent to those skilled in the art upon consideration of the practice of one or more embodiments of the invention disclosed herein. Therefore, the examples in this application and herein are merely illustrative, and the true scope and spirit of the invention are embodied in the exemplary claims listed below.
Claims
1. A method for treating hypertension by ablating perirenal adipose tissue around the kidneys using a focused ultrasound device, the method comprising: i) The acoustic focal zone generated by the focused ultrasound device is located within the perirenal adipose tissue surrounding the kidney, wherein the location of the acoustic focal zone is at least at a predetermined minimum distance from the renal capsule and renal fascia of the kidney; as well as ii) Apply focused ultrasound waves within the acoustic focal domain to the perirenal adipose tissue.
2. The method according to claim 1, wherein the acoustic focal region is spaced at least 3 mm away from the renal fibrous capsule and the renal fascia in the longitudinal direction along the acoustic focal region.
3. The method according to claim 1, wherein the acoustic focal region is spaced at least 2 mm apart from the renal fibrous capsule and the renal fascia in a direction perpendicular to the longitudinal axis of the acoustic focal region.
4. The method of claim 1, further comprising: Repeat steps i) and ii) until at least a portion of the perirenal adipose tissue surrounding the kidney has been traversed by the acoustic domain.
5. The method of claim 1, wherein the acoustic focusing path for forming the acoustic focal domain is selected to be remote from the hepatic flexure of the colon and the jejunum.
6. The method according to claim 1, wherein the location of the acoustic focal zone is at least at a predetermined minimum distance from the psoas major muscle.
7. The method of claim 1, wherein the perirenal adipose tissue is adipose tissue located at the lower pole of the kidney, and the focused ultrasound device is configured to deliver ultrasound energy through a posterior or lateral approach of the patient to establish the acoustic focusing path.
8. The method of claim 1, wherein the acoustic focal region is spaced at least 1.5 mm from the psoas major muscle in the axial direction along the acoustic focal region.
9. The method of claim 1, wherein the acoustic focal region is spaced at least 1 mm from the psoas major muscle in a direction perpendicular to the axis of the acoustic focal region.
10. The method of claim 1, wherein the process of applying focused ultrasound waves to the perirenal adipose tissue within the acoustic focal domain comprises: The perirenal adipose tissue was irradiated with the focused ultrasound to raise its temperature to 40 to 70 degrees Celsius.
11. The method of claim 10, wherein the process of applying focused ultrasound waves to the perirenal adipose tissue within the acoustic focal domain comprises: The perirenal adipose tissue was irradiated with the focused ultrasound to raise its temperature to 45 to 55 degrees Celsius.
12. The method of claim 1, wherein the process of applying focused ultrasound waves within the acoustic focal domain to the perirenal adipose tissue comprises: The perirenal adipose tissue is irradiated within the acoustic focal zone using the focused ultrasound for a duration between 1 second and 120 seconds.
13. A focused ultrasound device configured to treat hypertension by ablating perirenal adipose tissue around a patient's kidney using a focused ultrasound treatment probe, said focused ultrasound device comprising: A processor configured to control the focused ultrasound device to perform the following operations: The focused ultrasound device generates a target area for perirenal adipose tissue ablation; This generates multiple ablation target points spatially arranged within the target area, each ablation target point corresponding to the position where the acoustic focal zone of the focused ultrasound treatment probe is placed for ablation; and Focused ultrasound is applied to each of the plurality of ablation targets to ablate the perirenal adipose tissue within the target area.
14. The focused ultrasound device of claim 13, wherein the process of generating a target area for perirenal adipose tissue ablation comprises: A designated short axis section of the kidney and perirenal adipose tissue is obtained by selecting the short axis section of the kidney and perirenal adipose tissue with the largest perirenal adipose tissue cross-sectional area from a plurality of short axis sections of the kidney and perirenal adipose tissue, wherein each of the plurality of short axis sections of the kidney and perirenal adipose tissue is perpendicular to a first direction parallel to the short axis of the kidney; Obtain a designated short-axis boundary of the perirenal adipose tissue, the designated short-axis boundary corresponding to the boundary of the perirenal adipose tissue contained within the designated short-axis section of the kidney and the perirenal adipose tissue; A designated long axis section of the kidney and perirenal adipose tissue is obtained by selecting the long axis section of the kidney and perirenal adipose tissue with the largest cross-sectional area of perirenal adipose tissue from a plurality of long axis sections, wherein each of the plurality of long axis sections of the kidney and perirenal adipose tissue is perpendicular to a second direction parallel to the long axis of the kidney; Obtain a designated long axis boundary of the perirenal adipose tissue, the designated long axis boundary corresponding to the boundary of the perirenal adipose tissue contained within the designated long axis section of the kidney and the perirenal adipose tissue; as well as The target region is generated through the following steps: 1) By extending the enclosure region of the designated short axis boundary of the perirenal adipose tissue along the first direction, the extension length is the length of the enclosure region of the designated long axis boundary of the perirenal adipose tissue along the first direction, to obtain a first three-dimensional region; 2) A second three-dimensional region is obtained by extending the enclosed region of the designated long axis boundary of the perirenal adipose tissue along the second direction for a length equal to the length of the enclosed region of the designated short axis boundary of the perirenal adipose tissue along the second direction. as well as 3) Merge the first three-dimensional region and the second three-dimensional region to generate the target region.
15. The focused ultrasound device of claim 13, wherein the process of generating a plurality of ablation target points spatially arranged within the target region comprises: Multiple initial ablation targets are generated based on a predetermined boundary interval between adjacent acoustic focal domains, with each initial ablation target corresponding to an acoustic focal domain. as well as The initial ablation targets are deleted from a portion of the plurality of initial ablation targets that fall outside a certain area of the perirenal adipose tissue, in order to generate the plurality of ablation targets.
16. The focused ultrasound device according to claim 15, wherein the predetermined boundary interval distance includes row interval, column interval, and layer interval.
17. The focused ultrasound apparatus of claim 15, wherein the predetermined boundary interval between adjacent acoustic focal zones is less than 10 mm.
18. The focused ultrasound apparatus of claim 15, wherein the process of applying focused ultrasound waves to each of the plurality of ablation targets comprises: Focused ultrasound is applied to each of the plurality of ablation targets, such that non-adjacent ablation targets are irradiated sequentially.
19. The focused ultrasound device of claim 13, wherein the process of generating a plurality of ablation targets spatially arranged within the target region comprises: The specified size of the initial thermal focal zone is determined based on preset size parameters; Based on the predetermined boundary interval distance between adjacent initial thermal focal zones, multiple initial thermal focal zones with the specified size are spatially positioned within the target area, each initial thermal focal zone corresponding to an initial ablation target point used to generate the corresponding thermal focal zone; as well as Delete some of the initial ablation target points that fall outside the target region from the multiple initial ablation target points corresponding to the multiple initial thermal focal regions, so as to generate the multiple ablation target points.
20. The focused ultrasound device according to claim 19, wherein the preset size parameters include the temperature rise value of the corresponding initial ablation target point, the target temperature of the corresponding initial ablation target point, and the thermal conductivity of the perirenal adipose tissue.
21. The focused ultrasound apparatus of claim 13, wherein the process of applying focused ultrasound waves to each of the plurality of ablation targets comprises: Focused ultrasound is applied such that the focused ultrasound power reaching the perirenal adipose tissue is in the range between 5 W and 100 W.
22. The focused ultrasound apparatus of claim 13, wherein the process of applying focused ultrasound waves to each of the plurality of ablation targets comprises: Focused ultrasound is applied to each of the plurality of ablation targets, such that the maximum acoustic intensity reaching the perirenal adipose tissue in the acoustic focal region is between 100 W / cm². 2 With 4000W / cm 2 Within the range between.
23. The focused ultrasound apparatus of claim 13, wherein the process of applying focused ultrasound waves to each of the plurality of ablation targets comprises: Focused ultrasound is applied at frequencies in the range between 0.8 MHz and 1.7 MHz.
24. A focused ultrasound device configured to treat hypertension by ablating perirenal adipose tissue surrounding a patient's kidney, said focused ultrasound device comprising: Therapeutic framework; A focused ultrasound therapy probe, fixed to the treatment frame and configured to emit focused ultrasound waves to ablate perirenal adipose tissue, wherein the focused ultrasound therapy probe is movable in an axial direction parallel to the axis of the focused ultrasound therapy probe; and A first ultrasound imaging probe is mounted on the treatment frame, wherein the first ultrasound imaging probe is movable in the axial direction, and the first ultrasound imaging probe and the focused ultrasound treatment probe are configured to be independently driven to allow individual axial translation of each probe.
25. The focused ultrasound device according to claim 24, further comprising: A second ultrasound imaging probe is mounted outside the treatment frame, wherein the axis of the second ultrasound imaging probe always passes through the acoustic focal zone of the focused ultrasound treatment probe.
26. The focused ultrasound device according to claim 24, further comprising: A water tank, which is mounted on the treatment frame and contains acoustically coupled water; as well as A water bladder is mounted on the treatment frame and below the water tank, wherein the water bladder is configured to contact the patient's skin, wherein ultrasound waves emitted by the focused ultrasound treatment probe and the first ultrasound imaging probe propagate through the acoustically coupled water within the water tank and the water bladder to the patient.
27. The focused ultrasound device according to claim 26, further comprising: A pressure sensor is installed inside the water tank, wherein the pressure sensor is configured to measure the pressure inside the water tank, the pressure being caused by the acoustically coupled water and the water bladder; as well as A temperature sensor is installed inside the water tank, wherein the temperature sensor is configured to monitor the temperature of the acoustically coupled water.
28. The focused ultrasound device according to claim 26, further comprising: A first camera and a second camera are mounted on two opposite sides of the first ultrasound imaging probe, wherein the first camera and the second camera face the contact surface between the water bag and the patient's skin to obtain an image of the contact surface.
29. The focused ultrasound device according to claim 25, further comprising a control module having control commands.
30. The focused ultrasound apparatus of claim 29, further comprising an imaging ultrasound drive module connected to the first ultrasound imaging probe and the second ultrasound imaging probe and receiving control commands from the control module, wherein the imaging ultrasound drive module is configured to: Drive the first and second ultrasonic imaging probes to emit imaging ultrasonic waves; The returned imaging ultrasound waves are received through the first ultrasound imaging probe and the second ultrasound imaging probe; and An ultrasound image is generated based on the returned imaging ultrasound.
31. The focused ultrasound device of claim 29, further comprising a therapeutic ultrasound drive module connected to the focused ultrasound therapeutic probe and receiving control commands from the control module, wherein the therapeutic ultrasound drive module is configured to drive the focused ultrasound therapeutic probe to emit therapeutic ultrasound waves.
32. The focused ultrasound device of claim 29, further comprising a mechanical module coupled to the treatment frame and receiving control commands from the control module, wherein the mechanical module is configured to control the treatment frame to perform three-dimensional linear motion and three-dimensional angular rotation.
33. The focused ultrasound device according to claim 24, further comprising: A first motor is mounted on the treatment frame and configured to control the first ultrasound imaging probe to reciprocate along the axial direction; as well as A second motor is mounted on the treatment frame and configured to control the focused ultrasound treatment probe to reciprocate along the axial direction.
34. The focused ultrasound device of claim 26, further comprising a control module having control commands, and a water treatment module connected to the water tank via a water pipe connector and receiving control commands from the control module, wherein the water treatment module is configured to: The acoustically coupled water is received from the water tank through the water pipe joint; The acoustic coupling water is degassed to obtain degassed acoustic coupling water; and The degassed acoustically coupled water is delivered to the water tank through the water pipe joint.
35. The focused ultrasound device according to claim 34, wherein the dissolved oxygen in the degassed acoustic coupling water is less than or equal to 4 mg / L.
36. The focused ultrasound device of claim 27, further comprising a water treatment module connected to the pressure sensor and the temperature sensor, wherein the water treatment module is configured to: The volume of the acoustically coupled water is adjusted based on the pressure measured by the pressure sensor; and The temperature of the acoustically coupled water is adjusted based on the temperature measured by the temperature sensor.
